Monday 27th May 2013 |
Text too small? |
Vealls Ltd has named its preferred bidder for Cardrona Alpine Resort, the first step in a strategy to refocus on Singapore that is opposed by shareholder Elevation Capital Management.
Te Anau-based tourism company Real Journeys, whose businesses include the TSS Earnslaw and Milford Sound cruises, will make its first foray into skifields if the acquisition meets due diligence and gets shareholder approval.
Cardrona's operating assets were valued at A$40.9 million, according to Vealls' first-half accounts, and the skifield was the biggest source of earnings, at A$5.7 million, while the Australian company's biggest asset, some A$57 million held on deposit with banks, generated just A$509,000, reflecting low interest rates.
Vealls announced in February that it was cashing up its existing investment portfolio to focus on companies listed in Singapore after a strategic review. It appears to have resisted a call from Elevation Capital Management managing director Chris Swasbrook in February 2012 to return capital to shareholders using cash holdings and franking credits.
"I have a strong preference for a return of capital versus a redeployment of capital via Singapore," Swasbrook told BusinessDesk.
The Elevation Capital Value Fund held 38,000 Vealls capital shares according to its April disclosure, amounting to 2.5 percent of the firm's portfolio. Swasbrook said he was happy with that holding.
Vealls is winding up subsidiaries that don't conduct material business, selling its ski-field interests by June 30 and disposing of land holdings over the next two-to-three years. Following the asset sales, Vealls will use the proceeds to become an investment company and then give thought to listing itself on the Singapore Stock Exchange.
BusinessDesk.co.nz
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors